Cruentaren A binds F1F0 ATP synthase to modulate the Hsp90 protein folding machinery

ACS Chemical Biology

Volumn 9, Issue 4, 2014, Pages 976-985

  Hall, Jessica A ^a   Kusuma, Bhaskar Reddy ^a   Brandt, Gary E L ^a   Blagg, Brian S J ^a  

^a UNIVERSITY OF KANSAS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHAPERONE; CRUENTAREN A; EPIDERMAL GROWTH FACTOR RECEPTOR 2; HEAT SHOCK PROTEIN 70; HEAT SHOCK PROTEIN 90; PROTEIN KINASE B; PROTON TRANSPORTING ADENOSINE TRIPHOSPHATE SYNTHASE; PROTON TRANSPORTING ADENOSINE TRIPHOSPHATE SYNTHASE INHIBITOR; RAF PROTEIN; UNCLASSIFIED DRUG; F1F0-ATP SYNTHASE; MACROLIDE; PROTEIN BINDING;

AMINO TERMINAL SEQUENCE; ANTIPROLIFERATIVE ACTIVITY; ARTICLE; CARBOXY TERMINAL SEQUENCE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG MECHANISM; ENZYME ACTIVITY; ENZYME INHIBITION; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN FOLDING; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; WESTERN BLOTTING; ANTAGONISTS AND INHIBITORS; CHEMICAL STRUCTURE; CHEMISTRY; DOSE RESPONSE; DRUG EFFECTS; IC50; MCF 7 CELL LINE; METABOLISM; TUMOR CELL LINE;

BLOTTING, WESTERN; CELL LINE, TUMOR; DOSE-RESPONSE RELATIONSHIP, DRUG; HSP90 HEAT-SHOCK PROTEINS; HUMANS; INHIBITORY CONCENTRATION 50; MACROLIDES; MCF-7 CELLS; MITOCHONDRIAL PROTON-TRANSLOCATING ATPASES; MOLECULAR STRUCTURE; PROTEIN BINDING; PROTEIN FOLDING;

EID: 84899079603     PISSN: 15548929     EISSN: 15548937     Source Type: Journal    
DOI: 10.1021/cb400906e     Document Type: Article

References (39)

1. Pratt, W. B. (1993) The role of heat shock proteins in regulating the function, folding, and trafficking of the glucocorticoid receptor J. Biol. Chem. 268, 21455-21458
2. Csermely, P., Schnaider, T., Soti, C., Prohászka, Z., and Nardai, G. (1998) The 90-kDa molecular chaperone family: Structure, function, and clinical applications. A comprehensive review Pharmacol. Ther. 79, 129-168
3. Taipale, M., Jarosz, D. F., and Lindquist, S. L. (2010) HSP90 at the hub of protein homeostasis: emerging mechanistic insights Nat. Rev. Mol. Cell Biol. 11, 515-528
4. Xu, W. and Neckers, L. (2007) Targeting the molecular chaperone heat shock protein 90 provides a multifaceted effect on diverse cell signaling pathways of cancer cells Clin. Cancer Res. 13, 1625-1629
5. Chaudhury, S., Welch, T. R., and Blagg, B. S. J. (2006) Hsp90 as a target for drug development ChemMedChem 1, 1331-1340
6. da Silva, V. C. H. and Ramos, C. H. I. (2012) The network interaction of the human cytosolic 90 kDa heat shock protein Hsp90: A target for cancer therapeutics J. Proteomics 75, 2790-2802
7. Holzbeierlein, J., Windsperger, A., and Vielhauer, G. (2010) Hsp90: A drug target? Curr. Oncol. Rep. 12, 95-101
8. Prodromou, C. (2009) Strategies for stalling malignancy: Targeting cancers addiction to Hsp90 Curr. Top. Med. Chem. 9, 1352-1368
9. Wandinger, S. K., Richter, K., and Buchner, J. (2008) The Hsp90 chaperone machinery J. Biol. Chem. 283, 18473-18477
10. Whitesell, L. and Lindquist, S. L. (2005) Hsp90 and the chaperoning of cancer Nat. Rev. Cancer 5, 761-772
11. Kamal, A., Thao, L., Sensintaffar, J., Zhang, L., Boehm, M. F., Fritz, L. C., and Burrows, F. J. (2003) A high-affinity conformation of Hsp90 confers tumour selectivity on Hsp90 inhibitors Nature 425, 407-410
12. Kim, Y. S., Alarcon, S. V., Lee, S., Lee, M.-J., Giaccone, G., Neckers, L., and Trepel, J. B. (2009) Update on Hsp90 inhibitors in clinical trial Curr. Top. Med. Chem. 9, 1479-1492
13. Eskew, J. D., Sadikot, T., Morales, P., Duren, A., Dunwiddie, I., Swink, M., Zhang, X., Hembruff, S., Donnelly, A., Rajewski, R. A., Blagg, B. S., Manjarrez, J. R., Matts, R. L., Holzbeierlein, J. M., and Vielhauer, G. A. (2011) Development and characterization of a novel C-terminal inhibitor of Hsp90 in androgen dependent and independent prostate cancer cells BMC Cancer 11, 468
14. Matts, R. L., Dixit, A., Peterson, L. B., Sun, L., Voruganti, S., Kalyanaraman, P., Hartson, S. D., Verkhivker, G. M., and Blagg, B. S. J. (2011) Elucidation of the Hsp90 C-terminal inhibitor binding site ACS Chem. Biol. 6, 800-807
15. Yu, X. M., Shen, G., Neckers, L., Blake, H., Holzbeierlein, J., Cronk, B., and Blagg, B. S. J. (2005) Hsp90 inhibitors identified from a library of novobiocin analogues J. Am. Chem. Soc. 127, 12778-12779
16. Brandt, G. E. L., Schmidt, M. D., Prisinzano, T. E., and Blagg, B. S. J. (2008) Gedunin, a novel Hsp90 inhibitor: Semisynthesis of derivatives and preliminary structure-activity relationships J. Med. Chem. 51, 6495-6502
17. Pearl, L. H. (2005) Hsp90 and Cdc37-s chaperone cancer conspiracy Curr. Opin. Genet. Dev. 15, 55-61
18. Zhang, T., Li, Y., Yu, Y., Zou, P., Jiang, Y., and Sun, D. (2009) Characterization of celastrol to inhibit Hsp90 and Cdc37 interaction J. Biol. Chem. 284, 35381-35389
19. Patwardhan, C. A., Fauq, A., Peterson, L. B., Miller, C., Blagg, B. S. J., and Chadli, A. (2013) Gedunin inactivates the co-chaperone p23 protein causing cancer cell death by apoptosis J. Biol. Chem. 288, 7313-7325
20. Papathanassiu, A. E., MacDonald, N. J., Bencsura, A., and Vu, H. A. (2006) F1F0-ATP synthase functions as a co-chaperone of Hsp90-substrate protein complexes Biochem. Biophys. Res. Commun. 345, 419-429
21. Weigelt, S., Huber, T., Hofmann, F., Jost, M., Ritzefeld, M., Luy, B., Freudenberger, C., Majer, Z., Vass, E., Greie, J.-C., Panella, L., Kaptein, B., Broxterman, Q. B., Kessler, H., Altendorf, K., Hollósi, M., and Sewald, N. (2012) Synthesis and conformational analysis of efrapeptins Chem. - Eur. J. 18, 478-487
22. Papathanassiu, A., MacDonald, N., Emlet, D., and Vu, H. (2011) Antitumor activity of efrapeptins, alone or in combination with 2-deoxyglucose, in breast cancer in vitro and in vivo Cell Stress Chaperones 16, 181-193
23. Jundt, L., Steinmetz, H., Luger, P., Weber, M., Kunze, B., Reichenbach, H., and Höfle, G. (2006) Isolation and structure elucidation of cruentarens A and b - novel members of the benzolactone class of ATPase inhibitors from the Myxobacterium Byssovorax cruenta Eur. J. Org. Chem. 2006, 5036-5044
24. Kunze, B., Sasse, F., Wieczorek, H., and Huss, M. (2007) Cruentaren A, a highly cytotoxic benzolactone from Myxobacteria is a novel selective inhibitor of mitochondrial F1-ATPases FEBS Lett. 581, 3523-3527
25. Kunze, B., Steinmetz, H., Hofle, G., Huss, M., Wieczorek, H., and Reichenbach, H. (2006) Cruentaren, a new antifungal salicylate-type macrolide from Byssovorax cruenta (Myxobacteria) with inhibitory effect on mitochondrial ATPase Activity J. Antibiot. 59, 664-668
26. Dakubo, G. D. (2010) The Warburg phenomenon and other metabolic alterations of cancer cells, Mitochondrial Genetics and Cancer, pp 39-66, Springer, Berlin.
27. Capuano, F., Guerrieri, F., and Papa, S. (1997) Oxidative phosphorylation enzymes in normal and neoplastic cell growth J. Bioenerg. Biomembr. 29, 379-384
28. Miyata, Y., Nakamoto, H., and Neckers, L. (2013) The therapeutic target Hsp90 and cancer hallmarks Curr. Pharm. Des. 19, 347-65
29. Matts, R. L., Brandt, G. E. L., Lu, Y., Dixit, A., Mollapour, M., Wang, S., Donnelly, A. C., Neckers, L., Verkhivker, G., and Blagg, B. S. J. (2011) A systematic protocol for the characterization of Hsp90 modulators Bioorg. Med. Chem. 19, 684-692
30. Yun, B.-G., Huang, W., Leach, N., Hartson, S. D., and Matts, R. L. (2004) Novobiocin induces a distinct conformation of Hsp90 and alters Hsp90-cochaperone-client interactions Biochemistry 43, 8217-8229
31. Matts, R. L. and Manjarrez, J. R. (2009) Assays for identification of Hsp90 Inhibitors and biochemical methods for discriminating their mechanism of action Curr. Top. Med. Chem. 9, 1462-1478
32. Hartson, S. D., Irwin, A. D., Shao, J., Scroggins, B. T., Volk, L., Huang, W., and Matts, R. L. (2000) p50cdc37 is a nonexclusive Hsp90 cohort which participates intimately in Hsp90-mediated folding of immature kinase molecules Biochemistry 39, 7631-7644
33. Peng, X., Guo, X., Borkan, S. C., Bharti, A., Kuramochi, Y., Calderwood, S., and Sawyer, D. B. (2005) Heat Shock Protein 90 stabilization of ErbB2 expression is disrupted by ATP depletion in myocytes J. Biol. Chem. 280, 13148-13152
34. Symersky, J., Osowski, D., Walters, D. E., and Mueller, D. M. (2012) Oligomycin frames a common drug-binding site in the ATP synthase Proc. Natl. Acad. Sci. U.S.A. 109, 13961-13965
35. Guppy, M., Leedman, P., Zu, X., and Russell, V. (2002) Contribution by different fuels and metabolic pathways to the total ATP turnover of proliferating MCF-7 breast cancer cells Biochem. J. 364, 309-315
36. Wallace, D. C. (2012) Mitochondria and cancer Nat. Rev. Cancer 12, 685-698
37. Marcu, M. G., Schulte, T. W., and Neckers, L. (2000) Novobiocin and related coumarins and depletion of Heat Shock Protein 90-dependent signaling proteins J. Natl. Cancer Inst. 92, 242-248
38. Donnelly, A. C., Mays, J. R., Burlison, J. A., Nelson, J. T., Vielhauer, G., Holzbeierlein, J., and Blagg, B. S. J. (2008) The design, synthesis, and evaluation of coumarin ring derivatives of the novobiocin scaffold that exhibit antiproliferative activity J. Org. Chem. 73, 8901-8920
39. Kusuma, B. R., Brandt, G. E. L., and Blagg, B. S. J. (2012) Synthesis of cruentaren A Org. Lett. 14, 6242-6245